Cerebral Small Vessel Disease-Related Dementia: More Questions Than Answers

被引:27
|
作者
Elahi, Fanny M. [3 ,4 ,5 ]
Wang, Michael M. [1 ,2 ,6 ,7 ,8 ]
Meschia, James F. [9 ]
机构
[1] Univ Michigan, VA Ann Arbor Healthcare Syst, Dept Neurol, 2215 Fuller Rd,Bldg 31-221, Ann Arbor, MI 48105 USA
[2] Univ Michigan, Dept Mol & Integrat Physiol, VA Ann Arbor Healthcare Syst, 2215 Fuller Rd,Bldg 31-221, Ann Arbor, MI 48105 USA
[3] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY USA
[4] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY USA
[5] VA Bronx Healthcare Syst, Neurol Serv, New York, NY USA
[6] Univ Michigan, Dept Neurol, Ann Arbor, MI USA
[7] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI USA
[8] VA Ann Arbor Healthcare Syst, Neurol Serv, Ann Arbor, MI USA
[9] Mayo Clin, Dept Neurol, Jacksonville, FL USA
关键词
Alzheimer disease; biomarker; blood-brain barrier; dementia; magnetic resonance imaging; BLOOD-BRAIN-BARRIER; WHITE-MATTER HYPERINTENSITIES; MEDIAL TEMPORAL ATROPHY; VASCULAR RISK-FACTORS; RECENT LACUNAR STROKE; COGNITIVE FUNCTION; ALZHEIMER-DISEASE; CEREBROVASCULAR REACTIVITY; CLINICAL-CRITERIA; STATIN TREATMENT;
D O I
10.1161/STROKEAHA.122.038265
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cerebral small vessel disease (CSVD) has emerged as a common factor driving age-dependent diseases, including stroke and dementia. CSVD-related dementia will affect a growing fraction of the aging population, requiring improved recognition, understanding, and treatments. This review describes evolving criteria and imaging biomarkers for the diagnosis of CSVD-related dementia. We describe diagnostic challenges, particularly in the context of mixed pathologies and the absence of highly effective biomarkers for CSVD-related dementia. We review evidence regarding CSVD as a risk factor for developing neurodegenerative disease and potential mechanisms by which CSVD leads to progressive brain injury. Finally, we summarize recent studies on the effects of major classes of cardiovascular medicines relevant to CSVD-related cognitive impairment. Although many key questions remain, the increased attention to CSVD has resulted in a sharper vision for what will be needed to meet the upcoming challenges imposed by this disease.
引用
收藏
页码:648 / 660
页数:13
相关论文
共 50 条
  • [41] Lecanemab: More Questions Than Answers!
    Upinder Kaur
    Jaideep Reddy
    Ashutosh Tiwari
    Sasanka Chakrabarti
    Sankha Shubhra Chakrabarti
    Clinical Drug Investigation, 2024, 44 : 1 - 10
  • [42] STRESS - MORE QUESTIONS THAN ANSWERS
    HALE, R
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 1994, 51 (10): : 509 - 510
  • [43] Isoxsuprine: more questions than answers
    Elliott, J
    EQUINE VETERINARY JOURNAL, 2000, 32 (02) : 90 - 91
  • [44] Methotrexate: More questions than answers
    Wallace, CA
    JOURNAL OF RHEUMATOLOGY, 2000, 27 (08) : 1834 - 1835
  • [45] TOLBUTAMIDE - MORE QUESTIONS THAN ANSWERS
    BARCLAY, WR
    JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1971, 215 (01): : 108 - &
  • [46] Avastin: more questions than answers ...
    Desjardins, Annick
    Sampson, John H.
    JOURNAL OF NEUROSURGERY, 2012, 116 (02) : 336 - 339
  • [47] Mechatronics - More questions than answers
    Bradley, David
    MECHATRONICS, 2010, 20 (08) : 827 - 841
  • [48] STILL MORE QUESTIONS THAN ANSWERS
    不详
    NATURE, 1973, 244 (5416) : 389 - 390
  • [49] FINANCE - MORE QUESTIONS THAN ANSWERS
    TRASKA, MR
    HOSPITALS, 1985, 59 (24): : 60 - 60
  • [50] Neonicotinoids - More questions than answers
    Harrison, Bob
    AMERICAN BEE JOURNAL, 2008, 148 (04): : 337 - 339